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The frequency of hypertriglyceridemia is high in CKD patients, but few
medications are available for controlling this lipid parameter when renal
insufﬁciency advances. We evaluated the safety and efﬁcacy of long-term
treatment with rosuvastatin, one of the strong statins for hypercholesterolemic
control, on lipid abnormalities in patients with CKD stage 3 and above. The
protocol consisted of a 4-week run-in period and a 48-week treatment phase
with rosuvastatin. Inclusion criteria were CKD stage 3 and above with serum
low-density lipoprotein (LDL) cholesterol levels above 100mg/dL and
triglyceride levels above 150 mg/dL. Patients received 2.5 to 5.0 mg
rosuvastatin daily. Lipid parameters and myolysis-related indicators were
measured. Forty-nine patients (29 men and 20 women aged 61 7 9 years,
serum creatinine levels above 1.5 mg/dL) were enrolled in the study.
Rosuvastatin signiﬁcantly decreased (P/0.05) serum LDL cholesterol from 163
7 39 to 126 7 31 mg/dL and apolipoprotein B from 151 7 36 to 108 7
24mg/dL at 4 weeks and maintained these parameters at low levels.
Rosuvastatin also signiﬁcantly decreased (P ¼ 0.001) serum triglyceride levels
from 194 7 43mg/dL at baseline to 160 7 51mg/dL at 48 weeks. High-
density lipoprotein (HDL) cholesterol concentrations did not change from
baseline (56 7 16mg/dL) to 48 weeks of treatment (57 7 17mg/dL).
However, LDL/HDL ratio decreased signiﬁcantly (P ¼ 0.036) from 3.4 7 0.7 to
2.2 7 0.9, which approached the target level (2.0). During the rosuvastatin
treatment period, serum creatine kinase, aldolase, and myoglobin
concentrations did not change. In conclusion, rosuvastatin treatment improved
serum triglyceride level as well as the LDL/HDL ratio in hyperlipidemic patients
with CKD stage 3 and above, without serious adverse effects, suggesting that
rosuvastatin is useful to control not only hypercholesterolemia but also
hypertriglyceridemia in CKD patients.
http://dx.doi.org/10.1016/j.krcp.2012.04.599
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Subcutaneous arteriovenous ﬁstula in the forearm is a common vascular
access for hemodialysis. However, primary failure of native ﬁstula occurs
because of either thrombosis formation within the ﬁrst several weeks after
surgery or immature vein dilatation. To evaluate the effect of platelet inhibition
on ﬁstula thrombosis and maturation failure, we used an antiplatelet agent,
sarpogrelate hydrochloride, in our study. The study was designed as an open-
label, parallel, prospective, randomized study for 8 weeks, comparing patients
receiving sarpogrelate 300 mg/day (sarpogrelate group, n¼33) with controls
receiving no medication (n¼46). The primary outcome was ﬁstula patency
failure determined by pulse Doppler ultrasound examination of the
arteriovenous ﬁstula performed 8 weeks after surgery. Pulse wave velocity was
also measured to determine the ankle brachial pressure index (ABI). The drug
was well-tolerated and did not increase bleeding events during the 8-week
study period. In the sarpogrelate group, patency failure occurred in 1 of 33
patients (3.0%), and the occlusion rate was signiﬁcantly lower (P¼0.001) than
that in the control group (3 of 46 patients; 6.5%). Average blood ﬂow rate in the
sarpogrelate group was 5467174 mL/min, and was signiﬁcantly higher
(P¼0.036) than 4487183mL/min in the control group. However, the diameter
of the shunt vessel in the sarpogrelate group was 5.271.3 mm, which was not
different from 5.170.6 mm in the control group. The Vmax was not
signiﬁcantly different between two groups (1.0170.56 m/sec in the
sarpogrelate group and 0.8970.66 m/sec in the control group). In all patients
(n¼79), blood ﬂow correlated with ABI (r¼0.34, P¼0.045). Our results suggest
that sarpogrelate reduces the frequency of ﬁstula patency failure. Sarpogrelate
may maintain ﬁstula patency, which is necessary for hemodialysis, by
increasing ABI.
http://dx.doi.org/10.1016/j.krcp.2012.04.600
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To investigate nutritional status and body composition in different ages of
maintaining hemodialysis (HD) patients. 129 patients (male 62, female 67)
with the mean age 56.33714.14 years on HD were divided into four groups
with age under 40, 40-69, 60-69 and over 70 years. Body composition was
evaluated with Multi-frequency bioelectric impedance analysis (BIA) and 83
healthy subjects, matched for age and sex, were as the control. In all patients,
about 6.2% were underweight with body mass index (BMI) less than 18.5 Kg/
m2. The incidence of underweight were 0%, 6.2%, 4.8% and 11.1% in groups
under 40, 40-59, 60-69 and over 70 years respectively. Serum Creatinine, ALB,
pre-ALB and normalized protein catabolic rate (nPCR) were signiﬁcantly
decreased in patients over 70 years. The young patients under 40 years also
displayed lower nPCR and CHO value compared with that of group 40-59 years.
Body cell mass, lean tissue mass, lean tissue index and relative lean tissue mass
in HD patients were signiﬁcantly lower than that in age and sex matched
control group. Meanwhile, fat mass, fat tissue index and relative fat were
increase 20% than the control. They were less different between HD patients
and controls in age of 40-59 years, however, difference signiﬁcantly increased
in other three groups and changes were most obvious in patients over 70 years.
In conclusion, our study showed that nutritional status was signiﬁcantly
associated with the age in HD patients. Patients under 40 years and over 70
years old displayed much severer protein wasting and more fat tissue storage.
http://dx.doi.org/10.1016/j.krcp.2012.04.601
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Bioimpedance spectroscopy with body composition model is a validated
method to assess hydration and nutritional status in dialysis patients. The
aim of this study is to compare quality of life, nutrition status and
hydration status between hemodialysis and peritoneal dialysis patients.
There were 26 PD and 32 HD patients included in this study.
Multifrequency bioimpedance spectroscopy were measured by BCM-body
composition monitor (Fresenius medical care) device, the device provided
body composition parameters including Lean Tissue index (LTI) Fat tissue
index (FTI) and quantiﬁed over hydration status (OH). Quality of life was
measured by WHO-QOL-BREF questionnaire. Scheffe’s test was used for
comparison and po0.05 was considered as statistically signiﬁcant. All of
the PD patients had weekly Kt/V41.7 and all of the HD patients had
weekly Kt/V43.6. There were no differences in Charlson’s comobidity
index, food intake, protein intake, BMI, blood pressure and quality of life
between groups. LTI and FTI between PD (12.26þ3.65, 10.79þ5.84) and
HD (11.48þ3.48, 10.52þ4.67) patients were not statistically different. PD
patients had more over hydration when compare to HD patients
(16.18þ11.24 vs. 2.36þ11.07%OH/ECW po0.0001) and ECW to ICW ratio
was higher in PD patients (1.02þ0.21 vs. 0.89þ0.18 p¼0.035).
Parameters PD HD p-value
WHO-QOL 89.23þ14.19 88.85þ12.35 0.98
LTI (kg/m2) 12.26þ3.65 11.48þ3.48 0.70
FTI (kg/m2) 10.79þ5.84 10.52þ4.67 0.96
OH/ECW (%) 16.18þ11.24 2.36þ11.07 o0.0001
ECW/ICW 1.02þ0.21 0.89þ0.18 0.035
In conclusion, quality of life and Nutritional status were not difference
between PD and HD patients. PD patients had more over hydration and
ECW to ICW ratio as assessed by bioimpedance spectroscopy.
http://dx.doi.org/10.1016/j.krcp.2012.04.602
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